KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) Other Non Operating Income (2017 - 2025)

Historic Other Non Operating Income for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Q3 2025 value amounting to -$31.4 million.

  • Amneal Pharmaceuticals' Other Non Operating Income fell 148082.67% to -$31.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$16.7 million, marking a year-over-year increase of 5444.64%. This contributed to the annual value of $11.8 million for FY2024, which is 12887.39% up from last year.
  • Latest data reveals that Amneal Pharmaceuticals reported Other Non Operating Income of -$31.4 million as of Q3 2025, which was down 148082.67% from $8.3 million recorded in Q2 2025.
  • In the past 5 years, Amneal Pharmaceuticals' Other Non Operating Income ranged from a high of $8.3 million in Q2 2025 and a low of -$47.4 million during Q4 2023
  • Its 5-year average for Other Non Operating Income is -$868684.2, with a median of $3.9 million in 2021.
  • Its Other Non Operating Income has fluctuated over the past 5 years, first skyrocketed by 93562.95% in 2024, then plummeted by 148082.67% in 2025.
  • Quarter analysis of 5 years shows Amneal Pharmaceuticals' Other Non Operating Income stood at $6.6 million in 2021, then crashed by 44.31% to $3.7 million in 2022, then tumbled by 1383.73% to -$47.4 million in 2023, then skyrocketed by 104.58% to $2.2 million in 2024, then plummeted by 1545.67% to -$31.4 million in 2025.
  • Its Other Non Operating Income stands at -$31.4 million for Q3 2025, versus $8.3 million for Q2 2025 and $4.2 million for Q1 2025.